With Novel Technology, AiRNA Aims at Partnerships, Niche in RNAi Drugs Space

The company, which was established by Boston Biomedical CEO and Cequent Pharmaceuticals co-founder Chiang Li, is banking on a new kind of RNAi molecule that is shorter than standard siRNAs and asymmetrically structured.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.